Patient-reported financial toxicity among patients with liver cancer: a systematic review and meta-analysis
- 1School of Nursing, Beijing University of Chinese Medicine
- 2Medical and Health Analysis Center, Peking University
- 3Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital
Abstract
Objective: Financial toxicity (FT) refers to the negative impact of medical financial burden on patients’ overall health. The study aimed to quantify the prevalence and severity of patient-reported FT, identify the factors associated with FT in liver cancer patients, and thereby provide evidence to guide effective interventions to reduce the negative impacts of FT.
Methods: In this study the following peer-reviewed databases were systematically searched: PubMed, Web of Science, Embase, the Cochrane Library, CINAHL, China National Knowledge Infrastructure, Wanfang Data, VIP, and Sinomed. The search was conducted from the inception of each database to March 2, 2026. Two independent authors extracted data using a standardized data extraction tool and assessed the methodological quality of included studies using the Joanna Briggs Institute Critical Appraisal Tools. A random-effects model was applied to generate pooled estimates of FT rates and severity.
Results: Of the 13,412 articles, 39 were included in the study. Most studies were conducted in China (26/39, 66.67%). There was significant heterogeneity in the definition and measurement of FT. The pooled FT rate was 74% (95% CI: 61–85%), indicating high prevalence. The pooled FT score was 20.80 (95% CI: 19.70–21.92) for the COST (range 0–44) and 40.18 (95% CI: 27.12–53.24) for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (range 0–100), reflecting a moderate level of FT. These findings suggest that liver cancer patients present a high prevalence of FT, yet the overall severity remains moderately low.
Conclusion: The findings of this study indicate that FT is a common but moderate issue in liver cancer care. However, the lack of standardized measurement tools and inconsistent reporting methods have impaired the comparability of available evidence. Therefore, future research should develop a validated FT assessment for liver cancer and test targeted interventions to improve care and policy.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261345754 , identifier: CRD420261345754.
Related
- The Effect of Oral Isotretinoin on Quality of Life in Patients With Acne Vulgaris: A Systematic Review and Meta-Analysis of Patient-Reported Outcomes
- Financial toxicity burden among patients with cancer and cancer survivors in the UK: a cross-sectional study of prevalence and variation across recruitment pathways
- Artificial intelligence–enabled nursing surveillance for pediatric cancer immunotherapy: integrating biomarkers, patient-reported outcomes, and long-term toxicity management
- Financial toxicity profiles and associated factors among lung cancer patients receiving immunotherapy: a latent profile analysis
- Patient-reported and caregiver-reported outcomes in refractory ascites secondary to cirrhosis: A systematic review and meta-analysis
BibTeX
@article{li2026patientreported,
title = {{Patient-reported financial toxicity among patients with liver cancer: a systematic review and meta-analysis}},
author = {Shangjin Li and Yuntong Liu and Yimeng Zhang and Lu Ren and Shujin Yue and Xiaoda Li and Fanping Meng and Chunxiang Su and Yiyuan Zhang and Jiaying Wang},
journal = {Frontiers in Public Health},
year = {2026},
month = oct,
doi = {10.3389/fpubh.2026.1958294},
url = {https://www.frontiersin.org/articles/10.3389/fpubh.2026.1958294/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Patient-reported financial toxicity among patients with liver cancer: a systematic review and meta-analysis
AU - Shangjin Li
AU - Yuntong Liu
AU - Yimeng Zhang
AU - Lu Ren
AU - Shujin Yue
AU - Xiaoda Li
AU - Fanping Meng
AU - Chunxiang Su
AU - Yiyuan Zhang
AU - Jiaying Wang
PY - 2026
DA - 2026/10/15
JO - Frontiers in Public Health
DO - 10.3389/fpubh.2026.1958294
UR - https://www.frontiersin.org/articles/10.3389/fpubh.2026.1958294/full
AB - Objective: Financial toxicity (FT) refers to the negative impact of medical financial burden on patients’ overall health. The study aimed to quantify the prevalence and severity of patient-reported FT, identify the factors associated with FT in liver cancer patients, and thereby provide evidence to guide effective interventions to reduce the negative impacts of FT. Methods: In this study the following peer-reviewed databases were systematically searched: PubMed, Web of Science, Embase, the Cochrane Library, CINAHL, China National Knowledge Infrastructure, Wanfang Data, VIP, and Sinomed. The search was conducted from the inception of each database to March 2, 2026. Two independent authors extracted data using a standardized data extraction tool and assessed the methodological quality of included studies using the Joanna Briggs Institute Critical Appraisal Tools. A random-effects model was applied to generate pooled estimates of FT rates and severity. Results: Of the 13,412 articles, 39 were included in the study. Most studies were conducted in China (26/39, 66.67%). There was significant heterogeneity in the definition and measurement of FT. The pooled FT rate was 74% (95% CI: 61–85%), indicating high prevalence. The pooled FT score was 20.80 (95% CI: 19.70–21.92) for the COST (range 0–44) and 40.18 (95% CI: 27.12–53.24) for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items (range 0–100), reflecting a moderate level of FT. These findings suggest that liver cancer patients present a high prevalence of FT, yet the overall severity remains moderately low. Conclusion: The findings of this study indicate that FT is a common but moderate issue in liver cancer care. However, the lack of standardized measurement tools and inconsistent reporting methods have impaired the comparability of available evidence. Therefore, future research should develop a validated FT assessment for liver cancer and test targeted interventions to improve care and policy. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261345754 , identifier: CRD420261345754.
SN - 2296-2565
ER -